Patents by Inventor Tarlochan S. Nijjar

Tarlochan S. Nijjar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-abeta antibodies
    Patent number: 11434283
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Anti-Abeta antibodies
    Patent number: 11434285
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220275067
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 1, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Philip James DOLAN, III, Tarlochan S. NIJJAR, Svetlana ALEXANDER, Robin BARBOUR, Stephen Jed TAM
  • Anti-Abeta Antibodies
    Publication number: 20220242940
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 4, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 11345749
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 31, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220153821
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 19, 2022
    Inventors: Tarlochan S. NIJJAR, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark E. RENZ
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220089702
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 24, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin BARBOUR, Svetlana ALEXANDER, Mark RENZ, Shuning GAI, Tarlochan S. NIJJAR, Philip James DOLAN, III, Philip PAYNE
  • Anti-Abeta Antibodies
    Publication number: 20220089762
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: March 24, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-transthyretin antibodies
    Patent number: 11267877
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 8, 2022
    Inventors: Joshua Reginald Salmans, Svetlana Alexander, Robin Barbour, Jeffrey N. Higaki, Tarlochan S. Nijjar
  • Anti-transthyretin antibodies
    Patent number: 11267878
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: March 8, 2022
    Assignees: Neotope Neuroscience Limited, University Health Network
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Anti-Abeta Antibodies
    Publication number: 20220049009
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 17, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041700
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041699
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041701
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • ANTI-TRANSTHYRETIN ANTIBODIES
    Publication number: 20210371507
    Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Application
    Filed: May 4, 2021
    Publication date: December 2, 2021
    Inventors: YUE LIU, TARLOCHAN S. NIJJAR, AVIJIT CHAKRABARTTY, JEFFREY N. HIGAKI
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20210261652
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 26, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark E. RENZ
  • ANTI-TRANSTHYRETIN ANTIBODIES
    Publication number: 20210188956
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Anti-transthyretin antibodies
    Patent number: 11028158
    Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 8, 2021
    Assignees: Prothena Biosciences Limited, University Health Network
    Inventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Antibodies recognizing tau
    Patent number: 10961302
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 30, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Humanized Antibodies That Recognize Alpha-Synuclein
    Publication number: 20210040188
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: June 16, 2020
    Publication date: February 11, 2021
    Applicant: Prothena Biosciences Limited
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar